Tatiane Bomfim Ribeiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tatiane Bomfim Ribeiro has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Daniela Oliveira de Melo
Universidade Federal de São Paulo, Brasil; Universidade Federal de São Paulo, Brasil
5 shared publications - Fredi Alexander Diaz-Quijano
University of São Paulo, School of Public Health, Department of Epidemiology - Laboratory of Causal Inference in Epidemiology (LINCE-USP). São Paulo, SP, Brazil
4 shared publications - Airton Tetelbom Stein
Universidade Federal de Ciências da Saúde de Porto Alegre, Brazil
3 shared publications Ana Paula Vieira Araujo
Department of Pharmacy, University Hospital of Sao Paulo, University of Sao Paulo, Sao Paulo, Brazil
2 shared publicationsBenjamin Djulbegovic
Department of Computational & Quantitative Medicine, Beckman Research Institute, City of Hope, Duarte, California, USA; Division of Health Analytics, Evidence-Based Medicine & Comparative Effectiveness Research, 1500 East Duarte Rd, Duarte, California, USA
2 shared publicationsIztok Hozo
Department of Mathematics, Indiana University NW Gary, Indiana, USA
2 shared publications
Latest Publications
- Open Access
- 23 July 2025
- Published by Jornal de Assistencia Farmaceutica e Farmacoeconomia in JORNAL DE ASSISTÊNCIA FARMACÊUTICA E FARMACOECONOMIA
- Vol. 10 (3)
Cost-minimization and budget impact analysis of bypassing agents in hemophilia A with inhibitors: a Brazilian study
OBJECTIVE: The aim of the study was to compare the treatment with plasma-derived activated prothrombin complex concentrate (APCC) and recombinant activated FVII (rFVIIa) in patients with Hemophilia A with inhibitors, analyzing the costs and budget impact of prophylactic and on-demand treatment in the Brazilian Unified Health System (In Portuguese, Sistema Único de Saúde [SUS]). METHODS: This study performs a Cost-Minimization Analysis (CMA) and a Budget Impact Model) BIM for APCC versus rFVIIa in the prophylaxis and on-demand treatment in SUS perspective, based on analysis of guidelines and public databases from Brazil. RESULTS: The cost per patient for prophylaxis is estimated to be lower with APCC than in rFVIIa for the maximum dose with an incremental cost difference of BRL 2,730,798 (APCC BRL 3,325,894 versus rFVIIa BRL 6,056,692). The BIM estimated that 5 years after the partial substitution of rFVIIa for APCC (30% and 70%, respectively) brings the potential saving of BRL 201,622,888 considering prophylaxis in adults and BRL 83,095,850 in children. For on-demand usage, the amount saved could be BRL 42,696,097 in adults and BRL 17,596,556 in children. CONCLUSION: This analysis suggests a potential cost saving from payer’s perspective (SUS) using APCC instead rFVIIa for Hemophilia A patients with inhibitors, mainly for prophylaxis. The results could potentially bring value to patients and payers as resources could be reallocated to provide more care with the same budget, considering patient clinic response.
- 23 July 2025
- Published by Jornal de Assistencia Farmaceutica e Farmacoeconomia in JORNAL DE ASSISTÊNCIA FARMACÊUTICA E FARMACOECONOMIA
- Vol. 10 (3)
Open AccessCost-minimization and budget impact analysis of bypassing agents in hemophilia A with inhibitors: a Brazilian study
OBJECTIVE: The aim of the study was to compare the treatment with plasma-derived activated prothrombin complex concentrate (APCC) and recombinant activated FVII (rFVIIa) in patients with Hemophilia A with inhibitors, analyzing the costs and budget impact of prophylactic and on-demand treatment in the Brazilian Unified Health System (In Portuguese, Sistema Único de Saúde [SUS]). METHODS: This study performs a Cost-Minimization Analysis (CMA) and a Budget Impact Model) BIM for APCC versus rFVIIa in the prophylaxis and on-demand treatment in SUS perspective, based on analysis of guidelines and public databases from Brazil. RESULTS: The cost per patient for prophylaxis is estimated to be lower with APCC than in rFVIIa for the maximum dose with an incremental cost difference of BRL 2,730,798 (APCC BRL 3,325,894 versus rFVIIa BRL 6,056,692). The BIM estimated that 5 years after the partial substitution of rFVIIa for APCC (30% and 70%, respectively) brings the potential saving of BRL 201,622,888 considering prophylaxis in adults and BRL 83,095,850 in children. For on-demand usage, the amount saved could be BRL 42,696,097 in adults and BRL 17,596,556 in children. CONCLUSION: This analysis suggests a potential cost saving from payer’s perspective (SUS) using APCC instead rFVIIa for Hemophilia A patients with inhibitors, mainly for prophylaxis. The results could potentially bring value to patients and payers as resources could be reallocated to provide more care with the same budget, considering patient clinic response.
- Open Access
- 9 January 2025
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 41 (1) , 1-34
Development of a value assessment framework for Health Technology Assessment in rare diseases drugs: insights from a Delphi study in Brazil
Objective: The aim of this study is to propose and validate a value assessment framework for Health Technology Assessment (HTA) for rare diseases drugs in Brazil. Methods: A scoping review was performed to identify criteria used by HTA agencies in countries with public healthcare systems when evaluating orphan drugs. Based on the findings, a criteria framework for rare disease drugs was proposed for Brazil. Content validity was conducted over three rounds using Delphi technique and content validity ratio (CVR) approach was employed to evaluate the ratings from the eighteen stakeholders (experts and patients). Results: Twenty-nine HTA criteria for rare disease drugs were identified to compose the Brazilian framework. After three Delphi rounds, the final value framework comprised fifteen criteria categorized into four domains: disease-related factors, treatment-related factors, social and political factors, and economic factors. Among the most well-rated criteria by the CVR, considering the relevance attribute, were “relevance of outcomes for a rare disease,” “impact on patient’s quality of life,” “price negotiation,” and “adjusted cost-effectiveness threshold.” On the other hand, “budget impact threshold,” “innovative nature of treatment,” and “willingness to accept greater uncertainty in clinical evidence” received negative evaluations and were excluded from the final framework. Conclusions: A value assessment framework validated by key stakeholders of rare diseases in Brazil could contribute to improve HTA transparency, decision making, and efficiency of the healthcare system, and inspire the development of a local guidance for rare-disease HTA.
- 9 January 2025
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 41 (1) , 1-34
Open AccessDevelopment of a value assessment framework for Health Technology Assessment in rare diseases drugs: insights from a Delphi study in Brazil
Objective: The aim of this study is to propose and validate a value assessment framework for Health Technology Assessment (HTA) for rare diseases drugs in Brazil. Methods: A scoping review was performed to identify criteria used by HTA agencies in countries with public healthcare systems when evaluating orphan drugs. Based on the findings, a criteria framework for rare disease drugs was proposed for Brazil. Content validity was conducted over three rounds using Delphi technique and content validity ratio (CVR) approach was employed to evaluate the ratings from the eighteen stakeholders (experts and patients). Results: Twenty-nine HTA criteria for rare disease drugs were identified to compose the Brazilian framework. After three Delphi rounds, the final value framework comprised fifteen criteria categorized into four domains: disease-related factors, treatment-related factors, social and political factors, and economic factors. Among the most well-rated criteria by the CVR, considering the relevance attribute, were “relevance of outcomes for a rare disease,” “impact on patient’s quality of life,” “price negotiation,” and “adjusted cost-effectiveness threshold.” On the other hand, “budget impact threshold,” “innovative nature of treatment,” and “willingness to accept greater uncertainty in clinical evidence” received negative evaluations and were excluded from the final framework. Conclusions: A value assessment framework validated by key stakeholders of rare diseases in Brazil could contribute to improve HTA transparency, decision making, and efficiency of the healthcare system, and inspire the development of a local guidance for rare-disease HTA.
- Open Access
- 16 July 2024
- Published by Universidad Industrial de Santander in Salud UIS
- Vol. 56 (1)
Converging pathways: bringing community, student initiatives, and a systematic review project in COVID-19 pandemic
Introduction: In early January 2020, when the COVID-19 pandemic broke out, in vitro and animal studies showed preliminary positive results for repurposing drugs. Healthcare professionals had to critically assess the vast and emerging literature with an evidence-based approach to best clinical practices. Objective: The objective of this paper was to describe and reflect on the integration of a meta-research with a university extension program to promote critical reading of COVID-19 scientific studies among undergraduates. The meta-research aims to map the evidence and to estimate the prevalence of biases in comparative studies evaluating repurposing drugs for the treatment of COVID-19 during the pandemic. Methods: We integrated an online training on literature critical appraisal with a systematic review of methods. We searched for “COVID-19” and repurposed drug-related terms in MEDLINE, Embase, Cochrane Library, and LILACS by January 10th, 2022. Two independent researchers reviewed titles and abstracts and comparative studies had data fully extracted, including risk-of-bias. Results: A total of 171 students in Brazil signed into the online critical appraisal course. Of those, 24 were invited to collaborate with the meta-research, after robust evidence critical appraisal training. During the COVID-19 pandemic (2020-2021), 30.896 references assessed repurposing drug were identified and 6.246 papers were included. Our preliminary data showed 146 randomized controlled trials (RCT) with the word “randomized” in the title and 146 cohort studies identified by the word “cohort” in the title or Conclusions: The health emergency, there was an important volume of articles on interventions for COVID-19. Our preliminary results suggest that less than 5% of these studies were comparative longitudinal studies, being that most of the pertinent articles represent a challenge to be critically assessed, and probably have low level of evidence for clinical decision making. Our extension activity highlighted the interests of undergraduate healthcare students in developing skills on critical review of scientific articles. Thus, the experience of integrating university extension activity with research allows linking the community with knowledge generation.
- 16 July 2024
- Published by Universidad Industrial de Santander in Salud UIS
- Vol. 56 (1)
Open AccessConverging pathways: bringing community, student initiatives, and a systematic review project in COVID-19 pandemic
Introduction: In early January 2020, when the COVID-19 pandemic broke out, in vitro and animal studies showed preliminary positive results for repurposing drugs. Healthcare professionals had to critically assess the vast and emerging literature with an evidence-based approach to best clinical practices. Objective: The objective of this paper was to describe and reflect on the integration of a meta-research with a university extension program to promote critical reading of COVID-19 scientific studies among undergraduates. The meta-research aims to map the evidence and to estimate the prevalence of biases in comparative studies evaluating repurposing drugs for the treatment of COVID-19 during the pandemic. Methods: We integrated an online training on literature critical appraisal with a systematic review of methods. We searched for “COVID-19” and repurposed drug-related terms in MEDLINE, Embase, Cochrane Library, and LILACS by January 10th, 2022. Two independent researchers reviewed titles and abstracts and comparative studies had data fully extracted, including risk-of-bias. Results: A total of 171 students in Brazil signed into the online critical appraisal course. Of those, 24 were invited to collaborate with the meta-research, after robust evidence critical appraisal training. During the COVID-19 pandemic (2020-2021), 30.896 references assessed repurposing drug were identified and 6.246 papers were included. Our preliminary data showed 146 randomized controlled trials (RCT) with the word “randomized” in the title and 146 cohort studies identified by the word “cohort” in the title or Conclusions: The health emergency, there was an important volume of articles on interventions for COVID-19. Our preliminary results suggest that less than 5% of these studies were comparative longitudinal studies, being that most of the pertinent articles represent a challenge to be critically assessed, and probably have low level of evidence for clinical decision making. Our extension activity highlighted the interests of undergraduate healthcare students in developing skills on critical review of scientific articles. Thus, the experience of integrating university extension activity with research allows linking the community with knowledge generation.
- Open Access
Pooled evidence precision of clinical trials on hydroxychloroquine for Covid-19 treatment was stabilized eight months after the outbreak
OBJECTIVE: At the beginning of 2020, hydroxychloroquine showed promising in vitro activity for Covid-19 and several studies were oriented to assess its safety and efficacy. However, after a few months, hydroxychloroquine has proved ineffective. The randomized controlled trials (RCTs) developed quickly and in different settings represent the scientific community’s capacity to assess drug repositioning effectiveness during a sanitary crisis. Therefore, a critical evaluation of the evidence generated can guide future efforts in analogous situations. We aimed to analyze the RCTs assessing the efficacy of hydroxychloroquine in treating Covid-19, describe their internal validity and power, and evaluate their contribution to the precision of the combined evidence for assessing the mortality outcome. STUDY DESIGN AND SETTINGS: This meta-research included RCTs assessing hydroxychloroquine to treat patients diagnosed with Covid-19. It was part of an umbrella systematic review of methods/meta-research (PROSPERO: CRD42022360331) that included a comprehensive search in MEDLINE, EMBASE, Cochrane Library, and the Latin America Database - Lilacs. We retrieved studies published until January 10th, 2022. The risk of bias was assessed using Risk of Bias (RoB) 2.0. We analyzed methodology of the studies, precision and random error change through time from pooled evidence, study comparators, patient important outcome, power in different magnitude of effects proxy. RESULTS: A total of 22 RCT were included, from that 17 (77%) assessed hospitalized patients and five (23%) outpatients setting. Mortality was related as primary endpoint in only 4 studies, however half of the studies included composite endpoints including mortality as a component. The internal validity analysis using RoB2 found that eight studies (36%) had a high risk of bias. Only one study had sufficient power to evaluate a moderate magnitude of effect (RR = 0,7 on mortality). The standard error to evaluate efficacy on mortality did not change appreciably after October 2020. From Oct 2020 to Dec 2021, 18 additional studies were published with 2,429 patients recruited. CONCLUSION: This meta-research highlights the impact that collaborative, and network scientific research have on informing clinical decision-making. Duplicate efforts create research waste as precision analysis shows that after October 2020, there was not appreciably changes in the precision of the pooled RCT evidence to estimate the hydroxychloroquine effect on mortality. What is new?: After Oct2020, grouped RCT on the use of hydroxychloroquine in Covid-19 showed that precision estimate has not been appreciably modified in subsequent studies. At least 18 RCT (n=2,429) could potentially be saved through collaborative work. Most individual studies did not have sufficient power to assess the size of moderate effect size on mortality. Strengthening cooperation and integrating research centers can decrease research waste.
Open AccessPooled evidence precision of clinical trials on hydroxychloroquine for Covid-19 treatment was stabilized eight months after the outbreak
OBJECTIVE: At the beginning of 2020, hydroxychloroquine showed promising in vitro activity for Covid-19 and several studies were oriented to assess its safety and efficacy. However, after a few months, hydroxychloroquine has proved ineffective. The randomized controlled trials (RCTs) developed quickly and in different settings represent the scientific community’s capacity to assess drug repositioning effectiveness during a sanitary crisis. Therefore, a critical evaluation of the evidence generated can guide future efforts in analogous situations. We aimed to analyze the RCTs assessing the efficacy of hydroxychloroquine in treating Covid-19, describe their internal validity and power, and evaluate their contribution to the precision of the combined evidence for assessing the mortality outcome. STUDY DESIGN AND SETTINGS: This meta-research included RCTs assessing hydroxychloroquine to treat patients diagnosed with Covid-19. It was part of an umbrella systematic review of methods/meta-research (PROSPERO: CRD42022360331) that included a comprehensive search in MEDLINE, EMBASE, Cochrane Library, and the Latin America Database - Lilacs. We retrieved studies published until January 10th, 2022. The risk of bias was assessed using Risk of Bias (RoB) 2.0. We analyzed methodology of the studies, precision and random error change through time from pooled evidence, study comparators, patient important outcome, power in different magnitude of effects proxy. RESULTS: A total of 22 RCT were included, from that 17 (77%) assessed hospitalized patients and five (23%) outpatients setting. Mortality was related as primary endpoint in only 4 studies, however half of the studies included composite endpoints including mortality as a component. The internal validity analysis using RoB2 found that eight studies (36%) had a high risk of bias. Only one study had sufficient power to evaluate a moderate magnitude of effect (RR = 0,7 on mortality). The standard error to evaluate efficacy on mortality did not change appreciably after October 2020. From Oct 2020 to Dec 2021, 18 additional studies were published with 2,429 patients recruited. CONCLUSION: This meta-research highlights the impact that collaborative, and network scientific research have on informing clinical decision-making. Duplicate efforts create research waste as precision analysis shows that after October 2020, there was not appreciably changes in the precision of the pooled RCT evidence to estimate the hydroxychloroquine effect on mortality. What is new?: After Oct2020, grouped RCT on the use of hydroxychloroquine in Covid-19 showed that precision estimate has not been appreciably modified in subsequent studies. At least 18 RCT (n=2,429) could potentially be saved through collaborative work. Most individual studies did not have sufficient power to assess the size of moderate effect size on mortality. Strengthening cooperation and integrating research centers can decrease research waste.
- 8 April 2023
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 159, 151-158
Increasing FDA-accelerated approval of single-arm trials in oncology (1992 to 2020)
- 8 April 2023
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 159, 151-158
Increasing FDA-accelerated approval of single-arm trials in oncology (1992 to 2020)
- Open Access
Factors associated with higher quality of clinical practice guidelines and their recommendations for the pharmacological treatment of depression: a systematic review
Objective The objective of this study was to assess the quality of clinical practice guidelines (CPGs) for the pharmacological treatment of depression along with their recommendations and factors associated with higher quality. Design We conducted a systematic review that included CPGs for the pharmacological treatment of depression in adults. Data sources We searched for publications from 1 January 2011 to 31 December 2021, in MEDLINE, Cochrane Library, Embase, PsycINFO, BVS and 12 other databases and guideline repositories. Eligibility criteria for selecting studies We included CPGs containing recommendations for the pharmacological treatment of depression in adults at outpatient care setting, regardless of whether it met the U.S. National Academy of Medicine criteria, or not. If a CPG included recommendations for both children and adults, they were considered. No language restriction was applied. Data extraction and synthesis Data extraction was also conducted independently and in duplicate, a process that was validated in a previous project. The quality of the CPGs and their recommendations were assessed by three independent reviewers using Appraisal of Guidelines for Research and Evaluation (AGREE II) and Appraisal of Guidelines for Research and Evaluation-Recommendations Excellence (AGREE-REX). A CPG was considered to be of high quality if AGREE II Domain 3 was ≥60%; while their recommendations were considered high if AGREE-REX Domain 1 was ≥60%. Results Seventeen out of 63 (27%) CPGs were classified as high quality, while 7 (11.1%) had high-quality recommendations. The factors associated with higher-scoring CPGs and recommendations in the multiple linear regression analyses were ‘Handling of conflicts of interest’, ‘Multiprofessional team’ and ‘Type of institution’. ‘Inclusion of patient representative in the team’ was also associated with higher-quality recommendations. Conclusions The involvement of professionals from diverse backgrounds, the handling of conflicts of interest, and the inclusion of patients’ perspectives should be prioritised by developers aiming for high-quality CPGs for the treatment of depression.
Open AccessFactors associated with higher quality of clinical practice guidelines and their recommendations for the pharmacological treatment of depression: a systematic review
Objective The objective of this study was to assess the quality of clinical practice guidelines (CPGs) for the pharmacological treatment of depression along with their recommendations and factors associated with higher quality. Design We conducted a systematic review that included CPGs for the pharmacological treatment of depression in adults. Data sources We searched for publications from 1 January 2011 to 31 December 2021, in MEDLINE, Cochrane Library, Embase, PsycINFO, BVS and 12 other databases and guideline repositories. Eligibility criteria for selecting studies We included CPGs containing recommendations for the pharmacological treatment of depression in adults at outpatient care setting, regardless of whether it met the U.S. National Academy of Medicine criteria, or not. If a CPG included recommendations for both children and adults, they were considered. No language restriction was applied. Data extraction and synthesis Data extraction was also conducted independently and in duplicate, a process that was validated in a previous project. The quality of the CPGs and their recommendations were assessed by three independent reviewers using Appraisal of Guidelines for Research and Evaluation (AGREE II) and Appraisal of Guidelines for Research and Evaluation-Recommendations Excellence (AGREE-REX). A CPG was considered to be of high quality if AGREE II Domain 3 was ≥60%; while their recommendations were considered high if AGREE-REX Domain 1 was ≥60%. Results Seventeen out of 63 (27%) CPGs were classified as high quality, while 7 (11.1%) had high-quality recommendations. The factors associated with higher-scoring CPGs and recommendations in the multiple linear regression analyses were ‘Handling of conflicts of interest’, ‘Multiprofessional team’ and ‘Type of institution’. ‘Inclusion of patient representative in the team’ was also associated with higher-quality recommendations. Conclusions The involvement of professionals from diverse backgrounds, the handling of conflicts of interest, and the inclusion of patients’ perspectives should be prioritised by developers aiming for high-quality CPGs for the treatment of depression.
- Open Access
Early Real-World Data to Assess Benefits and Risks of COVID-19 Vaccines: A Systematic Review of Methods
Since the authorization of the first COVID-19 vaccines in December 2020, multiple studies using real-world data (RWD) have been published to assess their effectiveness/safety profile. This systematic review aimed to characterize the methods and outcomes of studies using RWD for assessment of COVID-19 vaccines, four months after vaccine approval. MEDLINE and EMBASE were searched to identify published studies until 6 May 2021. Two independent researchers selected relevant publications and extracted data from included studies. The risk of bias was assessed using New-Castle Ottawa tools. After screening 1086 studies, 15 were included. Out of the 15 studies, 12 (80%) followed a cohort design, 8 (53%) were based on USA data, 7 (47%) assessed health care professionals, and 14 articles (93%) assessed the BNT162b2 vaccine. Data sources included institutional databases, electronic health records, and patient-generated data. The primary endpoint mainly described was SARS-CoV-2-infection. Hospitalization and mortality were assessed in 2 studies. For the comparability domain, six studies (40%) had a high risk of bias. A few months after the beginning of COVID-19 vaccination, Real-world Evidence (RWE) provided timely safety surveillance and comparative effectiveness with findings that showed similar findings to Randomized control trial (RCT). Most of the initiatives assessed BNT162b2 and were conducted in the USA and used healthcare workers’ data.
Open AccessEarly Real-World Data to Assess Benefits and Risks of COVID-19 Vaccines: A Systematic Review of Methods
Since the authorization of the first COVID-19 vaccines in December 2020, multiple studies using real-world data (RWD) have been published to assess their effectiveness/safety profile. This systematic review aimed to characterize the methods and outcomes of studies using RWD for assessment of COVID-19 vaccines, four months after vaccine approval. MEDLINE and EMBASE were searched to identify published studies until 6 May 2021. Two independent researchers selected relevant publications and extracted data from included studies. The risk of bias was assessed using New-Castle Ottawa tools. After screening 1086 studies, 15 were included. Out of the 15 studies, 12 (80%) followed a cohort design, 8 (53%) were based on USA data, 7 (47%) assessed health care professionals, and 14 articles (93%) assessed the BNT162b2 vaccine. Data sources included institutional databases, electronic health records, and patient-generated data. The primary endpoint mainly described was SARS-CoV-2-infection. Hospitalization and mortality were assessed in 2 studies. For the comparability domain, six studies (40%) had a high risk of bias. A few months after the beginning of COVID-19 vaccination, Real-world Evidence (RWE) provided timely safety surveillance and comparative effectiveness with findings that showed similar findings to Randomized control trial (RCT). Most of the initiatives assessed BNT162b2 and were conducted in the USA and used healthcare workers’ data.
- 31 January 2022
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 148, 193-195
Single-arm clinical trials that supported FDA accelerated approvals have modest effect sizes and were at high risk of bias
- 31 January 2022
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 148, 193-195
Single-arm clinical trials that supported FDA accelerated approvals have modest effect sizes and were at high risk of bias
- Open Access
The Impact of Legislation on Covid-19 Mortality in a Brazilian Federative Unit was Mediated by Social Isolation
Background This study aimed to estimate the effect of restrictive laws on actual social isolation and COVID-19 mortality. Moreover, we evaluated how community adherence, measured with an index of social isolation, would mediate the lockdown effect on COVID-19 mortality. Methods This ecological study assessed the legislations published until June 30, 2020, in the Brazilian state of Ceará. We performed a systematic review and classification of restrictive norms and estimated their immediate effect on social isolation, measured by an index based on mobile data, and the subsequent impact on COVID-19 mortality (three weeks later). A mediation analysis was performed to estimate the effect of rigid lockdown on mortality that was explained for effective social isolation. Results The social isolation index showed an increase of 11.9% (95% CI: 2.9% - 21%) during the days in which a rigid isolation norm (lockdown) was implemented. Moreover, this rigid lockdown was associated with a reduction of 26% (95% CI: 21% - 31%) in the three-week-delayed mortality. We also calculated that the rigid lockdown had the indirect effect, i.e., mediated by adherence to social isolation, of reducing COVID-19 mortality by 38.24% (95% CI: 21.64% to 56.07%). Therefore, the preventive effect of this norm was fully explained by the actual population adherence, reflected in the social isolation index. On the other hand, mandatory mask use was associated with 11% reduction in COVID-19 mortality (95% CI: 8% −13%). Conclusions We estimated the effect of quarantine regulations on social isolation and evidenced that a rigid lockdown law led to a reduction of COVID-19 mortality in one state of Brazil. In addition, the mandatory masks norm was an additional determinant of the reduction of this outcome.
Open AccessThe Impact of Legislation on Covid-19 Mortality in a Brazilian Federative Unit was Mediated by Social Isolation
Background This study aimed to estimate the effect of restrictive laws on actual social isolation and COVID-19 mortality. Moreover, we evaluated how community adherence, measured with an index of social isolation, would mediate the lockdown effect on COVID-19 mortality. Methods This ecological study assessed the legislations published until June 30, 2020, in the Brazilian state of Ceará. We performed a systematic review and classification of restrictive norms and estimated their immediate effect on social isolation, measured by an index based on mobile data, and the subsequent impact on COVID-19 mortality (three weeks later). A mediation analysis was performed to estimate the effect of rigid lockdown on mortality that was explained for effective social isolation. Results The social isolation index showed an increase of 11.9% (95% CI: 2.9% - 21%) during the days in which a rigid isolation norm (lockdown) was implemented. Moreover, this rigid lockdown was associated with a reduction of 26% (95% CI: 21% - 31%) in the three-week-delayed mortality. We also calculated that the rigid lockdown had the indirect effect, i.e., mediated by adherence to social isolation, of reducing COVID-19 mortality by 38.24% (95% CI: 21.64% to 56.07%). Therefore, the preventive effect of this norm was fully explained by the actual population adherence, reflected in the social isolation index. On the other hand, mandatory mask use was associated with 11% reduction in COVID-19 mortality (95% CI: 8% −13%). Conclusions We estimated the effect of quarantine regulations on social isolation and evidenced that a rigid lockdown law led to a reduction of COVID-19 mortality in one state of Brazil. In addition, the mandatory masks norm was an additional determinant of the reduction of this outcome.
- 1 March 2021
- Published by Bentham Science Publishers Ltd. in Current Diabetes Reviews
- Vol. 17 (3) , 304-316
Association Between Intra-Hospital Uncontrolled Glycemia and Health Outcomes in Patients with Diabetes: A Systematic Review of Observational Studies
Background: Many people are still getting affected by uncontrolled glycemic events during hospital admission, which encompasses hypoglycemia, hyperglycemia, and high glycemic variability. Introduction: Primary studies have shown an association of glycemic dysregulation with increased length of hospital stay and mortality among overall patients, however, there is no systematic review of current evidence on the association between uncontrolled in-hospital glycemia in patients with diabetes and health outcomes. This study aimed to systematically review the current evidence on the association between uncontrolled in-hospital glycemia in patients with diabetes and health outcomes. Methods: The association between glycemic dysregulation and health outcomes for inpatients with diabetes was systematically reviewed. PubMed, Embase, and LILACS databases were searched. Two independent reviewers were involved in each of the following steps: screening titles, abstracts, and fulltexts; assessing the methodological quality; and extracting data from included reviews. Descriptive analysis method was used. Results: Seven cohort studies were included, and only two had a prospective design, consisting of 7,174 hospitalized patients with diabetes. In-hospital occurrence of hypoglycemia, hyperglycemia, and glycemic variability were assessed, and outcomes were mortality, infections, renal complications, and adverse events. Among the exposure and outcomes, an association was observed between severe hypoglycemia and mortality, hyperglycemia and infection, and hyperglycemia and adverse events. Conclusion: In-hospital uncontrolled glycemia in patients with diabetes is associated with poor health outcomes. More studies should be conducted for proper investigation because diabetes is a complex condition. Effects of glycemic dysregulation should be investigated on the basis of overall health of a patient instead from only organ-target perspective, which makes the investigation difficult.
- 1 March 2021
- Published by Bentham Science Publishers Ltd. in Current Diabetes Reviews
- Vol. 17 (3) , 304-316
Association Between Intra-Hospital Uncontrolled Glycemia and Health Outcomes in Patients with Diabetes: A Systematic Review of Observational Studies
Background: Many people are still getting affected by uncontrolled glycemic events during hospital admission, which encompasses hypoglycemia, hyperglycemia, and high glycemic variability. Introduction: Primary studies have shown an association of glycemic dysregulation with increased length of hospital stay and mortality among overall patients, however, there is no systematic review of current evidence on the association between uncontrolled in-hospital glycemia in patients with diabetes and health outcomes. This study aimed to systematically review the current evidence on the association between uncontrolled in-hospital glycemia in patients with diabetes and health outcomes. Methods: The association between glycemic dysregulation and health outcomes for inpatients with diabetes was systematically reviewed. PubMed, Embase, and LILACS databases were searched. Two independent reviewers were involved in each of the following steps: screening titles, abstracts, and fulltexts; assessing the methodological quality; and extracting data from included reviews. Descriptive analysis method was used. Results: Seven cohort studies were included, and only two had a prospective design, consisting of 7,174 hospitalized patients with diabetes. In-hospital occurrence of hypoglycemia, hyperglycemia, and glycemic variability were assessed, and outcomes were mortality, infections, renal complications, and adverse events. Among the exposure and outcomes, an association was observed between severe hypoglycemia and mortality, hyperglycemia and infection, and hyperglycemia and adverse events. Conclusion: In-hospital uncontrolled glycemia in patients with diabetes is associated with poor health outcomes. More studies should be conducted for proper investigation because diabetes is a complex condition. Effects of glycemic dysregulation should be investigated on the basis of overall health of a patient instead from only organ-target perspective, which makes the investigation difficult.